Alliancebernstein L.P. Cyma Bay Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $3.14 Million - $6.09 Million	248,739 Added 246.28%	349,739 $8.26 Million
Q2 2023 Aug 15, 2023	BUY	$7.47 - $10.95 $754,470 - $1.11 Million	101,000 New	101,000 $1.11 Million
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $183,352 - $361,374	-106,600 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.77 - $3.64 $1,108 - $1,456	400 Added 0.38%	106,600 $332,000
Q2 2021 Jul 30, 2021	BUY	$3.94 - $4.92 $33,884 - $42,312	8,600 Added 8.81%	106,200 $463,000
Q4 2020 Feb 08, 2021	SELL	$5.73 - $9.03 $51,570 - $81,270	-9,000 Reduced 8.44%	97,600 $560,000
Q2 2020 Aug 13, 2020	SELL	$1.41 - $4.25 $43,428 - $130,900	-30,800 Reduced 22.42%	106,600 $372,000
Q1 2020 May 14, 2020	BUY	$1.25 - $2.02 $25,750 - $41,612	20,600 Added 17.64%	137,400 $203,000
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $34,816 - $49,028	6,800 Added 6.18%	116,800 $598,000
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $300,080 - $677,536	49,600 Added 82.12%	110,000 $788,000
Q1 2019 May 14, 2019	SELL	$8.16 - $13.42 $59,568 - $97,966	-7,300 Reduced 10.78%	60,400 $802,000
Q2 2018 Aug 13, 2018	BUY	$10.66 - $14.38 $721,682 - $973,526	67,700 New	67,700 $909,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.